Michio Taya1,2, Viktoriya Paroder3,4, Eran Bellin5,6, Linda B Haramati3,5. 1. Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, 111 E 210th Street, Bronx, New York, NY, 10467, USA. michio.taya@gmail.com. 2. Graduate Medical Education, Virginia Mason Medical Center, 925 Seneca Street, Seattle, WA, 98101, USA. michio.taya@gmail.com. 3. Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, 111 E 210th Street, Bronx, New York, NY, 10467, USA. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. 5. Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, 111 E 210th Street, Bronx, New York, NY, 10467, USA. 6. Department of Epidemiology & Population Health, Albert Einstein College of Medicine and Montefiore Medical Center, 111 E 210th Street, Bronx, New York, NY, 10467, USA.
Abstract
OBJECTIVE: To determine all-cause mortality risk in patients with and without adrenal incidentaloma. METHODS: Retrospective cohort study of patients with CT abdomen performed within 24 h of emergency room presentation at an academic medical center from January 1, 2005, to December 31, 2009, without history of adrenal disease, adrenal lab testing, or cancer. Incidentaloma cohort identified by database query of imaging reports followed by manual review and matched to no-nodule controls at 3:1 on age ± 1 year and exam date ± 3 months. Mortality ascertained by in-hospital deaths and National Death Index query. Survival analysis performed with Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Among 42,575 adults with abdominal CT exams, 969 adrenal incidentaloma patients and 2907 no-nodule controls were identified. All 3876 individuals entered survival analysis with 31,182 person-years at risk (median follow-up 8.9 years [IQR, 6.9-10.7]). All-cause mortality was significantly higher among those with adrenal incidentalomas (353/969, 36.4%) compared with those without (919/2907, 31.6%; mortality difference 7.6 per 1000 person-years; multivariable-adjusted hazard ratio [aHR] 1.14; 95% CI, 1.003-1.29). Exploratory analyses, limited by missing covariates, found that adrenal incidentalomas were associated with significantly increased incidence of malignancy (aHR 1.61; 95% CI, 1.22-2.12), diabetes (aHR 1.43; 95% CI, 1.18-1.71), heart failure (aHR 1.32; 95% CI, 1.07-1.63), peripheral vascular disease (aHR 1.28; 95% CI, 1.95-1.56), renal disease (aHR 1.21; 95% CI, 1.01-1.44), and chronic pulmonary disease (aHR 1.22; 95% CI, 1.01-1.46) compared with controls. CONCLUSIONS: Adrenal incidentalomas are associated with increased mortality and may represent a clinically valuable biomarker. KEY POINTS: • Adrenal incidentalomas are associated with increased mortality. • Adrenal incidentaloma size is not predictive of mortality. • On exploratory analyses, adrenal incidentalomas are associated with chronic illnesses.
OBJECTIVE: To determine all-cause mortality risk in patients with and without adrenal incidentaloma. METHODS: Retrospective cohort study of patients with CT abdomen performed within 24 h of emergency room presentation at an academic medical center from January 1, 2005, to December 31, 2009, without history of adrenal disease, adrenal lab testing, or cancer. Incidentaloma cohort identified by database query of imaging reports followed by manual review and matched to no-nodule controls at 3:1 on age ± 1 year and exam date ± 3 months. Mortality ascertained by in-hospital deaths and National Death Index query. Survival analysis performed with Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Among 42,575 adults with abdominal CT exams, 969 adrenal incidentalomapatients and 2907 no-nodule controls were identified. All 3876 individuals entered survival analysis with 31,182 person-years at risk (median follow-up 8.9 years [IQR, 6.9-10.7]). All-cause mortality was significantly higher among those with adrenal incidentalomas (353/969, 36.4%) compared with those without (919/2907, 31.6%; mortality difference 7.6 per 1000 person-years; multivariable-adjusted hazard ratio [aHR] 1.14; 95% CI, 1.003-1.29). Exploratory analyses, limited by missing covariates, found that adrenal incidentalomas were associated with significantly increased incidence of malignancy (aHR 1.61; 95% CI, 1.22-2.12), diabetes (aHR 1.43; 95% CI, 1.18-1.71), heart failure (aHR 1.32; 95% CI, 1.07-1.63), peripheral vascular disease (aHR 1.28; 95% CI, 1.95-1.56), renal disease (aHR 1.21; 95% CI, 1.01-1.44), and chronic pulmonary disease (aHR 1.22; 95% CI, 1.01-1.46) compared with controls. CONCLUSIONS:Adrenal incidentalomas are associated with increased mortality and may represent a clinically valuable biomarker. KEY POINTS: • Adrenal incidentalomas are associated with increased mortality. • Adrenal incidentaloma size is not predictive of mortality. • On exploratory analyses, adrenal incidentalomas are associated with chronic illnesses.
Authors: Lincoln L Berland; Stuart G Silverman; Richard M Gore; William W Mayo-Smith; Alec J Megibow; Judy Yee; James A Brink; Mark E Baker; Michael P Federle; W Dennis Foley; Isaac R Francis; Brian R Herts; Gary M Israel; Glenn Krinsky; Joel F Platt; William P Shuman; Andrew J Taylor Journal: J Am Coll Radiol Date: 2010-10 Impact factor: 5.532
Authors: Michael T Corwin; James S Chalfant; Thomas W Loehfelm; Ghaneh Fananapazir; Ramit Lamba; William W Mayo-Smith Journal: AJR Am J Roentgenol Date: 2018-01-30 Impact factor: 3.959
Authors: Wiebke Schloetelburg; Ines Ebert; Bernhard Petritsch; Andreas Max Weng; Ulrich Dischinger; Stefan Kircher; Andreas Konrad Buck; Thorsten Alexander Bley; Timo Deutschbein; Martin Fassnacht Journal: Eur J Endocrinol Date: 2021-12-10 Impact factor: 6.664
Authors: Mark Sherlock; Andrew Scarsbrook; Afroze Abbas; Sheila Fraser; Padiporn Limumpornpetch; Rosemary Dineen; Paul M Stewart Journal: Endocr Rev Date: 2020-12-01 Impact factor: 19.871
Authors: Catherine D Zhang; Dingfeng Li; Ravinder Jeet Kaur; Andreas Ebbehoj; Sumitabh Singh; Elizabeth J Atkinson; Sara J Achenbach; William F Young; Wiebke Arlt; Walter A Rocca; Irina Bancos Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 6.134